Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
about
Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsStructural and Functional Analysis of the Pyocyanin Biosynthetic Protein PhzM from Pseudomonas aeruginosa † , ‡Structure of PqsD, a Pseudomonas Quinolone Signal Biosynthetic Enzyme, in Complex with AnthranilateThe Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-LactamsEvaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjectsLevofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.Setting and revising antibacterial susceptibility breakpoints.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen.Peritoneal fluid titer test for peritoneal dialysis-related peritonitis.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Pharmacological considerations for the proper clinical use of aminoglycosides.Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Population pharmacokinetic modelling, Monte Carlo simulation and semi-mechanistic pharmacodynamic modelling as tools to personalize gentamicin therapy.Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.Application of guidelines for aminoglycosides use in French hospitals in 2013-2014.Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia.Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.Animal model methodology: immunocompetent or leucopenic rats, which is the best? Results from a model of experimental pneumonia due to derepressed cephalosporinase-producing Enterobacter cloacae.Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen.No role for patient body weight on renal function assessment for drug dosing.Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.Antimicrobial Agents
P2860
Q26853629-121DCA8A-CEF9-4DCC-86C9-706A25C0582BQ27643657-3490EE7B-D733-4E30-B8FE-037EF95E8BD9Q27657088-27940CF2-5375-4643-80F6-A514DA0D31E4Q33696025-744CBCE3-18FF-4657-AD8D-1EE2D7C25EEDQ34077003-4B6D2F5B-2BA2-4614-84E1-21348CDA8976Q34274190-31122512-E87F-4558-AE87-024C3DDBABF8Q34297656-CA0A2199-B301-40DB-A43F-AF63CB2C3F26Q34632230-445FE433-EDBC-4FBD-9D62-49ED14EFF2EDQ34680572-35EFDC2B-E57C-45DF-8DE5-EBE76D71E0D8Q35913176-45B6CCD0-4129-44DA-94CB-016A8858E7B3Q36083619-5299EC26-3ACA-4026-B82D-B1086036FC0EQ36482780-2BE904A7-9EEE-4337-904D-C3A251E4969CQ37119964-A355F322-D843-40BF-B247-9380255B0E97Q37563029-0BCF11D1-446B-4976-BBBC-31C230E4CB3CQ37653435-91DA43E7-522F-45A2-B846-42252943E5A4Q37734670-60EABC21-F8AE-4F10-877F-BFABFCF2A78BQ37867260-B26B5B92-DF86-4651-817A-BE83C7ED2681Q37956403-91A599CE-AD3B-43AE-A8A7-AE53C37783D6Q38117578-1691D4AD-2F2E-4A1F-AB98-D631A7CE882DQ38790740-23FEA9A0-6A9D-4243-A61D-78BBB1F33BE4Q39071799-BCC70963-B6E1-4E79-8AF3-F8C4341E1BBAQ40307628-842FC1C5-057F-49D6-A0C6-7548BA7EA012Q40378234-EBBDABA3-23BF-4166-969C-8DC9C06B0CDCQ40982184-481B420E-103E-40FF-A6B7-BA3DF918D832Q41516734-8BFAFCBD-4B3F-4A25-87BF-8F8FF08454AAQ41696202-4E21B550-DF00-45B2-8B65-D000AF2FFABFQ42259839-B34F7B6B-93FD-40CE-A071-E8B4E07314A5Q44917117-CBA08EF3-A479-417A-B0E0-A008C4F757D3Q47176463-2C8B2459-C1C4-4B3F-BD92-4FF5DEF69111Q47223964-53300E59-EEA2-4861-883C-64A0D3843BE6Q52595189-6B358D34-C990-4521-9C72-7273328A6E63Q57549163-1A255430-4065-4A33-A285-FA74E347B5DC
P2860
Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@en
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@nl
type
label
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@en
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@nl
prefLabel
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@en
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@nl
P2093
P356
P1476
Treatment and outcome of Pseud ...... otic pharmacodynamic analysis.
@en
P2093
Godfrey K M Harding
Kiran Ubhi
P304
P356
10.1093/JAC/DKG403
P407
P577
2003-09-01T00:00:00Z